|
1. Biologie
|
|
|
|
2. Etiologie
|
|
|
|
2.7 Etiologie - Obésité
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
|
Mammography and overdiagnosis, revisited [Science-Based Medicine]
|
|
|
|
|
|
In
the US, we are very pro-screening, but that doesn’t necessarily mean
that our care is better. In any case, when it comes to mammography, the
value judgment to be made is simple to state but very hard to answer: Is
the small decrease in a woman’s chance of dying of breast cancer worth
the not inconsiderable risk of overdiagnosis and subsequent harm from
overtreatment?
|
|
|
|
|
|
|
5. Traitements
|
|
|
|
What side effects? Most consumers don’t read drug risk information [STAT]
|
|
|
|
|
|
The
upshot is that “mere exposure to risks does not automatically indicate
risk readership — no matter how fairly and well-balanced or clearly and
conspicuously those risks may be presented,” according to the authors of
the analysis, which was published online in the Journal of Risk
Research.
|
|
|
|
|
|
|
5.12 Immunothérapies
|
|
|
|
5.2 Pharma
|
|
|
|
Productivity Over the Years [In the Pipeline]
|
|
|
|
|
|
Looking
at the origins of the companies, about 46% of the approvals originate
at “traditional” pharma companies (of whatever size), about 25% come
from 1980s and 1990s VC-backed startups, and 29% from post-2001
VC-backed companies, which seems like a pretty respectable total.
|
|
|
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
NICE no for Opdivo in lung cancer, but CDF a possibility [PharmaTimes]
|
|
|
|
|
|
The
Institute did say that it would consider funding the drug via the
Cancer Drugs Fund to enable the collection of more data on its use, but
with a restriction - testing for biomarker PD-L1 - that is contrary to
its license and could deny treatment for up to two thirds of patients,
according to BMS.
|
|
|
|
|
|
|
R&D and the High Cost of Drugs [Science-Based Medicine]
|
|
|
|
|
|
Much
of the fundamental research is done in academic settings using public
money. The regulatory expense of bringing entirely new drugs to market
is high but much of that cost owes to a high attrition rate during
clinical trialing which itself owes to fundamental errors in choosing
promising candidates.
|
|
|
|
|
|
|
6.11 Patients
|
|
|
My Friend Sam [The New Yorker]
|
|
|
|
|
|
Sam
expressed his willingness to visit me as a ghost after his death, which
was an offer of unparalleled sweetness and also one I wasn’t sure I
wanted to accept.
|
|
|
|
|
|
|
|
|
6.2 Implants mammaires
|
|
|
|
6.6 Publications
|
|
|
|
6.7.2 Applis
|
|
|
Five Big Challenges Hospitals Face When Developing Mobile Apps [HIT Consultant]
|
|
|
|
|
|
“Your
app needs the functionality that people really want. It has to be as
fast and responsive. It has to be intuitive and simple to use. It has to
make things easier. It can’t just be another channel through which
users accomplish the same things they can do elsewhere. Unless you have
all of these requirements nailed, your chances of success are slim.”
|
|
|
|
|
|
|
6.9 Controverses
|
|
|